PHOTO
- Fakeeh Care’s performance reflects consistent growth in patient volumes and improved business mix with the ramp-up at Riyadh Hospital and growing contribution from its O&M business
Jeddah, KSA: Dr Soliman Abdel Kader Fakeeh Hospital Company and its Subsidiaries (“Fakeeh Care Group”, “FCG”, “Fakeeh Care”, the “Company” or the “Group”), a leading fully integrated academic healthcare provider listed on TASI (SYMBOL: 4017 and ISIN code SA562GSHUOH7), announces today its financial results for the nine-month period ended 30 September 2024, reporting revenue of SAR 2.0 billion, up by a solid 23.1% y-o-y. Net profit increased by a strong 49.4% y-o-y to SAR 195.3 million in 9M-2024 compared to the adjusted figure1 of SAR 130.7 million in 9M-2023, with net profit margin expanding c.170 basis points (bps) to 9.5% versus an adjusted1 7.9% in 9M-2023.
Growth during the period was primarily driven by higher patient footfall, an increased number of surgeries and deliveries, improved average implied revenue per patient, and a full nine-month contribution from the NEOM Hospital O&M contract. During 9M-2024, total cases served (including inpatient admissions and outpatient visits) reached c.1.3 million as of 30 September 2024 (excluding free follow-up visits), up by 12.9% y-o-y as Riyadh Hospital continues to ramp-up operations and with increased activity across the Group’s outpatient clinics.
Commenting on the Group’s performance, FCG’s President Dr. Mazen Soliman Fakeeh said: “Through the first nine months of 2024, Fakeeh Care has continued to deliver robust financial results with a strong revenue increase of 23.1% year-over-year to SAR 2.0 billion, reflecting consistent growth in patient volumes, a higher-value business mix, and an expanding contribution from our O&M business. Additionally, our Riyadh Hospital has been a significant contributor to our growth trajectory, with utilization reaching 71.3% as it ramps up towards full capacity, helping to drive improved cost efficiencies and margins. The increased footfall at our hospitals and centres demonstrates that more patients than ever are choosing us for our high standard of care and strong clinical outcomes.”
“In line with our post-IPO strategy, we have maintained a strong capital structure, settling SAR 1.2 billion in debt, which along with our cash generating abilities provides us with a robust financial position to continue our growth trajectory through targeted investments in expansion. Notably, our Madinah facility is on track for turnkey delivery by year-end, with infrastructure, equipment, and recruitment nearly complete—an essential milestone in our goal to enhance healthcare access across KSA. Additionally, we have committed SAR 218 million this quarter in CAPEX spend through construction contracts and have signed framework agreements to mark the initial stages of further expansion; in line with our longer-term growth targets to double our bed capacity and education facilities by 2028.”
During 9M-2024, Fakeeh also strengthened its integrated healthcare platform, achieving strong growth across all its business verticals. At the Healthcare and Medical-Related segments, Fakeeh Home Healthcare is now present in six major cities – with the latest two additions set to commence operations before year-end. Additionally, Fakeeh Emergency Medical Services grew significantly, with its fleet reaching 83 ambulances, supporting the Group's hub-and-spoke model and serving national events. Meanwhile, Fakeeh Vision now operates 16 branches, with three more set to open by year-end, reinforcing Fakeeh’s role as a comprehensive healthcare provider. Finally at the Education segment, Fakeeh College enrolled 352 new students across its various programs in September 2024, bringing the total to 1,736 students.
Finally, the Group secured numerous accreditations during the third quarter, including DSFH Riyadh’s Accreditation with Distinction for Nursing Excellence from the American Nurses Credentialing Centre. Additionally, DSFH Riyadh achieved institutional accreditation from the Saudi Commission for Health Specialties, along with the Saudi Board accreditation in Obstetrics and Gynaecology. Finally, Medical Fakeeh has achieved the prestigious Joint Commission International (JCI) accreditation (a distinction to healthcare facilities that meet globally recognized standards of quality and safety).
Dr. Mazen Soliman Fakeeh concluded: “Looking ahead, we are confident in the Group’s growth prospects, supported by strong utilization trends, especially in Riyadh as we expand its capacity and range of services, and continued operational enhancements at Jeddah Hospital. Additionally, a stronger focus on complex care, the ongoing delivery on our O&M business strategy and its potential expansion, and a favourable macroeconomic environment in Saudi Arabia further underpin our optimism for Fakeeh Care Group.”
Fakeeh Care Group’s complete 9M-2024 Earnings Release with management’s analysis of the Company’s performance is available for download on en.fakeeh.care.
About Fakeeh Care Group
Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. In 2022, after a period of significant growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.
In June 2024, Fakeeh Care Group successfully concluded its initial public offering (IPO) on the Tadawul. The IPO raised gross proceeds of SAR 2.9 billion (US$ 764 million) for the Company and the Selling Shareholders of which SAR 1.7 billion will be used to support and accelerate the Group’s growth strategy.
For further information, please contact:
Fakeeh Care Group
e-mail: investors@fakeeh.care
Forward-looking Statements
This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company’s business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.
These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.
The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company’s consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company’s financial information as reported under the IFRS.
[1] Comparable Net Profit figures for 9M-2023 and Q3-2023 are adjusted to exclude non-recurring financing income amounting to SAR 38.2 million and SAR 13.4 million, respectively. These amounts were related to a long-term receivable from FCG’s UAE related party, which was settled as of September 2023.